Introduction
Rheumatoid arthritis (RA) is an autoimmune disease in which tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) play a key role in the induction and progression of the disease. Therapies, antagonizing their effects, have been shown to be effective in controlling the symptoms as well as the activity of RA [1] [2] [3] . Several reports and data from registries confirm that the prevalence of type 2 diabetes mellitus (T2D) is increased in RA patients [4] . Several data, in recent years, showed that the excess of nutrients, secondary to over-nutrition, may activate the immune system [2] , leading to an increased production of inflammatory cytokines, and suggested that an inflammatorymediated process, mainly mediated by IL-1β, may be associated to T2D pathogenesis [1] . The magnitude of metabolic stresses, associated with a genetic predisposition, may lead to a continuous immune activation culminating into the disease [1] [2] [3] . These alterations are usually recognized in obese individuals, a condition frequently observed in RA patients, due to both inflammatory process and lifestyle changes, in which hypoxia, deriving from the uncoupled growth of adipose tissue and vasculature, recruits activated macrophages into the tissue, thus providing the pathological link between adipose tissue expansion and inflammation [5, 6] . Recently, several data have been reported about metabolic syndrome, insulin resistance, T2D and activation of the immune response, confirming the involvement of IL-1β in the recruitment of activated immune cells into pancreatic islets, in the β-cell apoptosis and islets fibrosis, as well as the efficacy of IL-1 blockers in controlling [7] these deleterious effects This review focusing the pathogenic role of IL-1β in the pathogenesis of both RA and T2D, the efficacy of IL-1 blocking agents in controlling these different but frequently associated diseases, will provide information suggesting that targeting IL-1β may be, in the future, a promising therapeutic choice in patients affected by both the diseases.
IL-1β production and release
The IL-1 family includes 11 members and among them, IL-1β plays a key role in many inflammatory diseases [8] . IL-1β is produced as inactive precursor, the pro-IL-1β, and after its proteolytic cleavage by active caspase-1, the active form of IL-1β, may be release. Caspase-1 activation requires the oligomerisation of the inflammasome, a complex intracellular proteic platform [9] . The inflammasome platform may prevent a uncontrolled production of IL-1β. In fact, patients with a genetically mediated deregulation of caspase-1 activation, leading to a continuous IL-1β production, develop a severe multi-organ sterile inflammations, such as cryopyrin-associated periodic syndrome and Muckle-Wells Syndrome [8] [9] [10] .
IL-1β is mainly produced by cells of innate immune system, [11] The IRAK4 phosphorylation precedes the phosphorylation of IRAK1, IRAK2 and tumor necrosis factor receptor-associated factor (TRAF) 6. The latter is an ubiquitin E3 ligase, that after association with ubiquitin E2 ligase complex, attaches K63-linked polyubiquitin chains to different IL-1 downstream intermediates, including TGF-β-activated protein kinase (TAK-1). After TRAF6/TAK-1 association, many transcription factors, such as NF-κB, and AP-1, which are involved in the inflammatory response, may be activated [8] [9] [10] [11] [12] . Furthermore, exogenous microbial products or exogenous cytokines, such as TNF-α IL-18, or IL-1β itself may provide additional signals, inducing the synthesis of IL-1β mRNA [8] [9] [10] [11] [12] .
A natural IL-1 Receptor Antagonist (IL-1RA), lacking agonistic activity in humans, is produced to modulate the IL-1β activity. IL-1RA, saturating both the binding sites of IL-1R and blocking the recruitment of IL-1RAcP, inhibits the formation of the IL-1RI/IL-1β/IL-1RAcP hetero-complex thus stopping the downstream cascade [13] .
RA and IL-1β pathogenesis
A large number of evidence in experimental models of arthritis as well as in humans confirmed the role of IL-1β in RA pathogenesis [14] . In fact, the synovial fluid of RA patients shows high IL-1β levels, produced by synovial tissue macrophages, activated T cells, fibroblasts and chondrocytes [15] . In affected joints, IL-1β modulates leucocyte recruitment, as well as the induction of matrix metalloproteinases (MMPs) and an higher tissue turnover [15, 16] , inducing cartilage degradation and inhibition of new matrix synthesis, thus leading to joint destruction, as confirmed in different animal models, in which the overexpression of IL-1β induces joints damage mirroring the pathology of RA [17] . Furthermore, IL-1β stimulates osteoclast differentiation and activity, via receptor activator of a nuclear factor kappa-B ligand (RANKL) expression in both the synovial fibroblasts and T cells of RA patients, a mechanism involved in bone erosion [18] [19] [20] [21] [22] . In addition, a vicious amplification loop, including IL-1β, TNF-α and IL-6, may contribute to the bone loss, via the modulation of synovial leucocyte infiltration and pannus organization [13] . Furthermore, in experimental RA models, spontaneous poly-arthropathy and bone erosions may be observed after deletion of the gene encoding for IL-1RA [20] [21] [22] [23] [24] [25] . On the contrary, a reduction of the cartilage breakdown associated with a preservation of cartilage matrix synthesis may be observed after the intra-articular transfer of the human IL-1RA gene in experimental models [26, 27] . Finally, the
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antagonism of IL-1β by using neutralizing antibodies, in adjuvant arthritis model, strongly decreased the disease activity [23, 24] .
The role of mononuclear cells in the production of IL-1 β during RA
Bone marrow progenitors, circulating monocytes, and tissue macrophages populate lymphoid and non-lymphoid tissues; an imbalance of their function may contribute to the RA pathogenesis as well as the development of comorbidities [28] . [30] . During RA, increased levels of both GM-CSF and M-CSF may be observed in the synovial fluid, thus contributing to the joint inflammation via the activation of M1 macrophages.
Furthermore, several inflammatory cytokines modulate the overproduction of GM-CSF and M-CSF by synovial fibroblasts and chondrocytes, thus inducing a self-perpetuating vicious loop [31] . In RA patients, the normal balance between these 2 macrophage subsets may be restored by conventional therapies and/or biologic agents [28] [29] [30] .
It is well known that T cells play a major roles in RA pathogenesis. In fact, RA is considered an autoimmune pathology in which autoreactive T cells are activated and involved in all the pathogenic steps of the disease. T cells, by the interaction with an unidentified antigen, proliferate and activate in early phases of the disease and directly drive the chronic inflammatory process [31] . Available literature confirms that T cells are activated and accumulated in the inflamed synovium, thus leading to perpetuation of the chronic inflammation and tissues remodeling and destruction. On these bases, experimental therapies targeting autoreactive T cells have been developed, including clinical trials with of anti-CD4 monoclonal antibodies, induction of oral tolerance, T cell vaccine and peptide therapy [32] . Although the preliminary results are encouraging, further studies are needed to fully elucidate the efficacy as well as the safety of these immunotherapies.
IL-1 blocking agents for RA
Anakinra, a recombinant form of a human IL-1RA, is a biologic drug antagonizing IL-1 activity. both IL-1β or IL-1α activity. This drug showed, in several clinical studies, a significant improvement in Canakinumab is a fully human anti-interleukin IL-1β monoclonal antibody, approved for the treatment of cryopyrin associated periodic syndrome [34] . Recently, it has been tested for the RA treatment [35, 36] . Its efficacy was assessed in a proof-of-concept study enrolling 53 active RA patients treated by methotrexate. The results showed that canakinumab significantly reduced the disease activity in enrolled population [35] . More recently, both the efficacy and safety of canakinumab, in RA patients, were evaluated in a phase II, randomized, double-blind, placebocontrolled trial, enrolling 274 patients. Patients were randomized to receive, in addition to methotrexate, , canakinumab or placebo every 2 weeks. The reported data showed that a large percentage of patients, treated with canakinumab, reached a significant clinical improvement when compared with placebo group without any concern about infection [36] .
IL-1β and T2D
Increased levels of glucose and free fatty acids (FFAs), such as oleate, palmitate and stearate may be able to induce an overproduction and release of inflammatory cytokines and chemokines by immune cells, adipose tissue, pancreatic islets and other insulin sensitive tissue. As far as the pancreatic islets are concerned, the final result of this process is the development of β-cell dysfunction and apoptosis, resembling both T1D and T2D pathogenesis [1-3].
Although in both pancreatic islets and adipose tissue the mechanisms of glucose induced activation of IL-1β are not fully understood, several observations have been reported concerning a possible link between immune cells and development of T2D [7] .
As far as the ability of increased glucose levels to modulate the production of inflammatory cytokines is concerned, conflicting results may be available in literature. modulates the release of IL-1β [39] . Although in this context, the pathogenic mechanisms of ROI are not still fully clarified, it must be pointed out that the β-cells display a very low reservoir of antioxidative enzymes, being more vulnerable to oxidative stress [1-3].
In the later stages of T2D, the deposition of amyloid in the islets further contribute to the release of IL-1β, via the activation of NLRP3-inflammasome [40] . Interestingly, deposition of amyloid in the islets is a hallmark of T2D, and human islet amyloid polypeptide (IAPP) seems to be related with the induction of IL-1β secretion both in macrophages and β-cells [40] . In addition, several other mechanisms have been proposed to explain the toxic effects of amyloid on β-cells, such as ER stress, defects in autophagy, enhanced production of pro-inflammatory cytokines, mitochondrial membrane damage, permeabilization of cell membranes, activation of Calpain-2, receptormediated mechanisms linked to oxidative stress, and finally the activation of cell death signaling pathways [41] .
As far as FFAs and their metabolites are concerned, it has been suggested that FFAs may act as either pro-or anti-inflammatory agents depending on the chemical structure. Saturated fatty acids (SFA) and polyunsaturated fatty acids (PUFA) significantly differ in their contributions to inflammation [42] . While SFAs have been shown to induce inflammation, PUFAs display an antiinflammatory effects by downregulating NF-kB, IL-1β, TNF-α and IL-6. It has been suggested that SFAs may activate G protein-coupled receptors (GPCRs), thus promoting the production and release of inflammatory cytokines such as IL-1β, IL-6 and TNF-α. In addition, SFAs, binding to Toll Like Receptors (TLR), mainly TLR2 and TLR4, peroxisome proliferator-activated receptors (PPARs) and GPCRs may further increase the inflammatory process. [42] [43] [44] [45] .
In this setting, the inflammasome, in presence of a possible metabolic stressor, may act as a sensor of metabolic danger, thus inducing IL-1β production and leading to the tissues damage [43] .
Furthermore, a vicious cycle of auto-inflammation may be observed in purified human β-cells, that after stimulation with IL-1β, increase their production and release of the same cytokine thus perpetuating the inflammation [44] . It has been shown that IL-1β auto-stimulation may be prevented by reducing NF-κB activity or, alternatively, by blocking IL-1R1 signalling, the latter also inhibiting FFAs-and glucose-induced upregulation of IL-1β [45] .
In addition, a failure in the anti-inflammatory axis has been shown, in the T2D patients, that display lower levels of IL-RA, in the endocrine pancreas, when compared to healthy controls [2, 46] . Finally, the evidence that hyperglycaemia may directly induce β-cell apoptosis, via the expression of the pro-apoptotic receptor Fas on β-cells, which may be further upregulated by glucose-induced IL-1β production by β-cells, confirms the metabolic trigger for the inflammatory process in T2D islets [1-3, 47, 48] .
Thus, we may suggest that the insulin deficiency, observed in T2D, is linked to different factors, such as lipotoxicity, glucotoxicity and amyloids deposits which are able to induce IL-1β overproduction, leading to β-cell dysfunction and subsequent T2D [40] .
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The role of monocytes/macrophages and production of IL-1β during T2D
The T2D is associated with the production of higher levels of inflammatory cytokines, which recruit immune cells into pancreatic islets [49] . It must be pointed out that resident macrophages, generally exhibiting M2-type phenotype (CD11b+ F4/80+ Ly-6C-cells) are actively involved during pancreatic physiological development. In fact, these cells may be detected in the embryonic epithelial duct cells, and are involved in the development of human pancreas [50] . In addition, several observations showed that macrophages colonise the pancreatic islets, supporting the development of β-cell mass during embryonic state and after birth [51, 52] .
Due to both the protective and homeostatic effects that pancreatic macrophages may exert, similarly to resident macrophages in other tissues, islets macrophages adapt themselves to this specific environment [7, 49] On the contrary, during T2D, under the effect of increased glucose concentrations, these M2-type cells switch to M1-type phenotype (CD11bhigh F4/80-/+Ly-6C+ cells) [53] which are characterized by an increased production of pro-inflammatory cytokines including IL-1β and higher expression of NLRP3-inflammasome [54, 55] . Taken together, these data suggest that during T2D, the islets macrophage shifts towards M1-type thus supporting the inflammatory process inside the pancreatic islets [7, 49, 53] .
Bimodal role of IL-1β in T2D
Despite evidence showing a pathogenic role of increased levels of IL-1β in suppressing the proliferation β-cells and their insulin secretion, the same cytokine, at lower concentrations may support the same cellular functions, suggesting a bimodal, dose-dependent effect [56, 57] 
IL-1 blocking agents for T2D
Both preclinical and clinical observations reported the efficacy of IL-1 antagonism therapy in T2D [62, 63] . Although IL-1 blocking agents seem to be ineffective in T1D patients [64] , recent preclinical evidence showed an IL-1β-driven pro-apoptotic function on pancreatic β-cells, thus suggesting a potential role of IL-1β in the early phases of T1D pathogenesis [64] . In this context, it has been proposed that a combination approach with anti-IL-1 drugs, in the early phases of T1D, might be attractive, to block the local β-cell inflammation and apoptosis and to promote regulatory Tlymphocyte responses [62] [63] [64] .
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Anakinra is biologic drug antagonizing IL-1 activity and licensed for the treatment of RA and many auto-inflammatory disorders [33, 65, 66] . The possible therapeutic effect of Anakinra in T2D has been tested in a clinical trial in which 70 T2D patients were randomized to receive anakinra or placebo. Anakinra significantly decreased the glycated hemoglobin (HbA1c) levels and this result was associated with an increase of C-peptide secretion, after 13 weeks of treatment [67] .
Furthermore, during the follow-up a reduction of the proinsulin/insulin ratio was observed after 39 weeks of anakinra withdrawal [68] . Further experiments, in animal models, confirmed that IL-1 antagonism was able to decrease inflammation in insulin sensitive tissues, and this result was associated with a reduction of macrophages infiltrates within the islet, leading to an improvement of β-cell function [69, 70] . In addition, an improvement of the glucose disposition index, during oral glucose tolerance test, was observed during anakinra treatment, in obese human subjects without T2D [71] . In this context, a randomized clinical trial, enrolling patients with impaired glucose tolerance, recently reported a significant improvement, of both insulin secretion and insulinogenic index, after 4 weeks of anakinra. [72] .
Gevokizumab, a recombinant humanized monoclonal antibody against IL-1β [73] , was able to induce a decrease of HbA1c levels, associated with an increase of C-peptide secretion, as well a reduction of C-reactive protein in T2D patients, at the dosages of 0.03-0.1 mg/kg [74] . On the contrary, higher dosages did not show any therapeutic effect. To explain this apparent paradox, it has been supposed that at higher dosages, fully neutralizing the IL-1β activity, might deprive β cells of the physiologic stimulus that this cytokine plays, to support both insulin secretion and B cell proliferation, as we already discussed [56, 57] . Canakinumab is a biological agent blocking IL-1β and was tested in a randomized clinical trial enrolling T2D patients. Fasting plasma glucose, insulin secretion rate and insulin levels were improved by canakinumab, after 4 week [75] . In addition, a large clinical trial is ongoing (ClinicalTrials.gov NCT01327846), in order to assess if Canakinumab
• Although in the past, the prevention of the joint destruction during RA was strongly emphasized, now a great interest is focused on associated comorbidities such as T2D.
• RA is an autoimmune disease in which IL-1β is a key component in the induction and progression of the disease, and therapies antagonizing its effects are effective in controlling the symptoms as well as the activity of RA.
• Many studies supported the pathogenic role of the IL-1β in T2D mirroring what has been observed in RA.
• The insulin deficiency, observed in T2D, is linked to different factors, such as lipotoxicity, glucotoxicity and amyloids deposits which are able to induce IL-1β overproduction.
• It has been reported that the increased concentrations of glucose may strongly influence the proinflammatory status of monocytes obtained from diabetic patients
• Both preclinical and clinical observations showed the efficacy of anti-IL-1 therapy in T2D .
• Clinical trials, enrolling RA patients with concomitant T2D, and designed to show if, anti-IL1treatments may reach the therapeutic targets of both the diseases, are ongoing.
• A better knowledge about the pathogenesis of these diseases as well as the possibility to treat, in the same patient, different diseases with the same drug, may allow both policy designers and physicians to choose the most effective therapies, lowering the costs.
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